Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Melanoma 13Carcinoma, Hepatocellular 13Neoplasm Metastasis 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Esophageal Neoplasms 9Colorectal Neoplasms 6Esophageal Squamous Cell Carcinoma 5Breast Neoplasms 5Recurrence 4Rectal Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Liver Neoplasms 3Head and Neck Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Radiation Pneumonitis 2Prostatic Neoplasms 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2

Interventions

Gemcitabine 6130-nm albumin-bound paclitaxel 4S 1 (combination) 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Electroporation 2zimberelimab 1surufatinib 1Irinotecan 1Immunotherapy 1Heavy Ion Radiotherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Pancreatic Cancer × Immunotherapy × Clear all
NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

Phase 2 Not yet recruiting
96 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡